Free Trial
NASDAQ:BOLT

Bolt Biotherapeutics (BOLT) Stock Price, News & Analysis

Bolt Biotherapeutics logo
$5.58 -0.07 (-1.15%)
As of 08/8/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Bolt Biotherapeutics Stock (NASDAQ:BOLT)

Key Stats

Today's Range
$5.50
$5.94
50-Day Range
$5.53
$6.71
52-Week Range
$5.20
$14.36
Volume
4,988 shs
Average Volume
19,807 shs
Market Capitalization
$10.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$50.00
Consensus Rating
Hold

Company Overview

Bolt Biotherapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
38th Percentile Overall Score

BOLT MarketRank™: 

Bolt Biotherapeutics scored higher than 38% of companies evaluated by MarketBeat, and ranked 701st out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bolt Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Bolt Biotherapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Bolt Biotherapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Bolt Biotherapeutics are expected to grow in the coming year, from ($1.61) to ($1.12) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bolt Biotherapeutics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bolt Biotherapeutics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Bolt Biotherapeutics has a P/B Ratio of 0.19. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Bolt Biotherapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    6.90% of the float of Bolt Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Bolt Biotherapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bolt Biotherapeutics has recently increased by 26.86%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Bolt Biotherapeutics does not currently pay a dividend.

  • Dividend Growth

    Bolt Biotherapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.90% of the float of Bolt Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Bolt Biotherapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bolt Biotherapeutics has recently increased by 26.86%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    3 people have searched for BOLT on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bolt Biotherapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.10% of the stock of Bolt Biotherapeutics is held by insiders.

  • Percentage Held by Institutions

    86.70% of the stock of Bolt Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Bolt Biotherapeutics' insider trading history.
Receive BOLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

BOLT Stock News Headlines

Trump set to Boost Social Security Checks by 400%?
If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative...
Bolt Biotherapeutics reports Q4 EPS (42c), consensus (35c)
See More Headlines

BOLT Stock Analysis - Frequently Asked Questions

Bolt Biotherapeutics' stock was trading at $10.7020 at the beginning of the year. Since then, BOLT stock has decreased by 48.0% and is now trading at $5.57.

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) posted its earnings results on Monday, May, 12th. The company reported ($5.80) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($6.80) by $1.00. The business earned $1.22 million during the quarter, compared to the consensus estimate of $0.77 million.

Bolt Biotherapeutics shares reverse split on the morning of Monday, June 9th 2025.A 1-20 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Sunday, June 8th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Bolt Biotherapeutics (BOLT) raised $150 million in an IPO on Friday, February 5th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities served as the underwriters for the IPO.

Top institutional shareholders of Bolt Biotherapeutics include Board of Trustees of The Leland Stanford Junior University (1.87%) and Geode Capital Management LLC (0.97%). Insiders that own company stock include Edgar Engleman, Vivo Capital Viii, Llc, William P Quinn and Sarah Nemec.
View institutional ownership trends
.

Shares of BOLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bolt Biotherapeutics investors own include Athenex (ATNX), NIO (NIO), Plug Power (PLUG), Alibaba Group (BABA), Moderna (MRNA), NVIDIA (NVDA) and XPeng (XPEV).

Company Calendar

Last Earnings
5/12/2025
Today
8/08/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:BOLT
CIK
354655
Fax
N/A
Employees
90
Year Founded
N/A

Price Target and Rating

High Price Target
$80.00
Low Price Target
$20.00
Potential Upside/Downside
+797.7%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($33.40)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$63.12 million
Net Margins
N/A
Pretax Margin
-1,741.26%
Return on Equity
-94.51%
Return on Assets
-59.07%

Debt

Debt-to-Equity Ratio
0.48
Current Ratio
3.13
Quick Ratio
3.13

Sales & Book Value

Annual Sales
$7.69 million
Price / Sales
1.39
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$29.89 per share
Price / Book
0.19

Miscellaneous

Outstanding Shares
1,920,000
Free Float
1,800,000
Market Cap
$10.69 million
Optionable
Not Optionable
Beta
0.90

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:BOLT) was last updated on 8/9/2025 by MarketBeat.com Staff
From Our Partners